Read + Share
Roblin X, Veyrard P, Bastide L, Berger AE, et al. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within
14-day treatment cycle in Crohn's disease. Aliment Pharmacol Ther 2022;56:77-83.
PMID: 35229331
|
 |
|
Roblin X, Veyrard P, Bastide L, Berger AE, et al. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within
14-day treatment cycle in Crohn's disease. Aliment Pharmacol Ther 2022;56:77-83.
PMID: 35229331
|
|
|
|